Cover Image
市場調查報告書

醫藥品的ADMET (藥物動力學毒性) 檢驗:全球市場預測 2015-2025年

Pharma Admet Testing: World Industry and Market Prospects 2015-2025

出版商 Visiongain Ltd 商品編碼 341090
出版日期 內容資訊 英文 156 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品的ADMET (藥物動力學毒性) 檢驗:全球市場預測 2015-2025年 Pharma Admet Testing: World Industry and Market Prospects 2015-2025
出版日期: 2015年10月01日 內容資訊: 英文 156 Pages
簡介

ADMET (藥物動力學毒性) 檢驗,是藥物開發不可或缺的部分。ADMET檢驗市場2014年達58億美元規模,收益大部分來自體內檢驗。

本報告提供全球ADMET (吸收、分佈、代謝、排泄、毒性) 檢驗市場現況與展望調查分析、促進成長要素與阻礙要素、市場整體/次市場/主要國家的市場收益預測、主要企業的評估、專家的採訪,及今後預測等彙整資料。

第1章 調查概要

第2章 ADMET檢驗的簡介

  • ADMET檢驗是什麼?
  • 生物學相似性的ADMET檢驗所扮演的角色
  • 實驗設計、實行

第3章 ADMET檢驗:全球市場

  • 醫藥品的R&D支出:各階段
    • 經濟ADMET檢驗市場帶來的影響
    • 大型製藥企業CRO的主要客戶
  • ADMET檢驗市場
    • 促進成長要素
    • 整體收益預測

第4章 ADMET檢驗:各市場區隔的收益

  • 收益最大的部門為何?
  • 10年的預測ADMET檢驗的需求擴大
  • 體外ADMET檢驗
    • 促進要素、阻礙要素
  • 體內ADMET檢驗
  • 電腦ADMET檢驗

第5章 ADMET檢驗:主要的已發展市場

  • ADMET檢驗的主要國家市場
  • ADMET檢驗:主要國家市場預測
  • 北美為藥物開發的目的地
    • 美國:ADMET檢驗的最大市場
    • 美國:ADMET檢驗收益預測
  • 歐盟5國的ADMET檢驗的展望
    • EU的臨床試驗規則的另寫
    • 歐盟5國:市場整體、主要國家市場預測
    • 德國:市場預測
    • 英國
    • 法國:市場預測
    • 義大利:市場預測
    • 西班牙:市場預測
  • 日本與近鄰新興市場競爭
    • 日本的ADMET檢驗的成長

第6章 ADMET檢驗:主要的新興市場

  • ADMET檢驗主要的新興市場
    • 實施新興市場上ADMET檢驗的優點
    • 實施新興市場上非臨床研究的課題
  • 新興ADMET檢驗市場的強力的成長預測
  • 亞太地區的ADMET:新興市場預測
    • 中國在2025年預計ADMET檢驗成為最大的新興市場
    • 臨床試驗據點的印度
    • 韓國
  • 俄羅斯
    • 變化需要的藥物開發需求
    • 俄羅斯的ADMET檢驗市場預測
  • 巴西:南美的最大藥物開發市場
    • 巴西的ADMET檢驗市場預測

第7章 ADMET檢驗產業上主要企業

  • Agilent Technologies, Inc.
  • Dassault Systemes:收購 Accelrys 成立BIOVIA
  • Cyprotex
  • Bio-Rad Laboratories, Inc.
  • Quintiles
  • Increasing Asian Regional Reach
  • Charles River Laboratories 前臨床服務的專門
  • Promega Corporation
  • Merck KGaA 收購 Sigma Aldrich

第8章 ADMET檢驗市場:產業趨勢

  • 優勢和弱點
  • 機會及威脅
  • STEP分析
  • 更有效率檢驗的技術改善
  • ADMET檢驗的經濟上檢討事項
  • 政治、規定的發展帶給ADMET檢驗影響

第9章 調查採訪

第10章 結論

圖表

目錄
Product Code: PHA0069

ADMET Products and Services - Your Guide to Trends and Revenue Potentials

The pharma ADMET testing market gains much interest from pharmaceutical companies as they look to implement more-predictive ADMET testing. That finding and many others appear in a new report by visiongain.

Absorption, distribution, metabolism, excretion and toxicology (ADMET) testing is an integral part of drug development. Visiongain estimates the ADMET testing market was valued at $5.80bn in 2014, with the majority of revenues being attributed to in vitro testing.

Our new report gives you 51 tables, 48 charts and three interviews. Discover the most lucrative areas in that industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions for those pharma R&D technologies. There is much opportunity in that fast moving market.

image1

image2

Forecasts from 2015-2025 and other analyses show you commercial prospects

Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments. Commercial drivers and restraints for each submarket are also provided, as are revenue forecasts to 2025.

  • In vitro ADMET testing
  • In vivo ADMET applications
  • In silico ADMET uses.

Our new study predicts the pharma ADMET testing market will expand throughout the forecast period, 2015 to 2025, driven by increased demand for that screening and advances in technology enhancing the reliability and predictive capabilities of those assays.

image3

image4

Leading companies and potential for market growth

Overall revenue for the pharma ADMET testing market will reach $10.51bn in 2019, our work forecasts. We predict strong revenue growth through to 2025, as drug developers select stronger product candidates for development, using ADMET technology.

Our work also analyses prominent companies in that market. See visiongain's analysis of leading companies, including these:

  • Agilent Technologies
  • BIOVIA
  • Cyprotex
  • Bio-Rad Laboratories
  • Quintiles
  • CMIC
  • Charles River Laboratories
  • WuXi PharmaTech
  • Promega Corporation
  • Sigma-Aldrich.

A company profile gives you the following information where available:

  • Recent historical revenues
  • Discussion of a company's activities, technologies and outlook
  • Brief assessment of the company's ADMET strategy.

With that information you will assess competitors' capabilities, progress, and commercial prospects, helping you stay ahead and benefit your reputation for insight.

image5

image6

National markets for those drug development technologies

Our study shows you prospects for ADMET sales in developed and developing countries. You will see individual revenue forecasts to 2025 for 12 countries:

  • United States
  • Japan
  • Germany, France, United Kingdom, Italy and Spain (EU5)
  • Brazil, Russia, India and China (BRIC)
  • South Korea.

With our analysis you will investigate regions with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.

What forces affect the pharma ADMET testing industry?

Our new report discusses issues and events affecting the pharmaceutical ADMET testing industry and market. You will find discussions, including qualitative analyses:

  • Rising demand for early ADMET testing
  • Developments in that drug screening technology.

You will see discussions of technological, commercial, and economic issues, with emphasis on the competitive landscape and business outlooks. Discover what the future holds.

How Pharma ADMET Testing: World Industry and Market Prospects 2015-2025 helps

In particular, our new investigation gives the following knowledge to benefit your work:

  • Revenue forecasts to 2025 for the pharma ADMET testing market - discover that industry's commercial prospects, finding what revenues and growth are possible
  • Revenue forecasts to 2025 for three submarkets - explore sales potentials of in vitro, in vivo and in silico testing
  • Revenue forecasts to 2025 for 12 leading national markets - US, EU5 (Germany, France, UK, Italy and Spain), Japan, Brazil, Russia, India, China and South Korea
  • Assessment of leading companies - assess competitors, exploring their product and service portfolios, strategic developments and commercial outlooks
  • Exclusive interviews with three companies - gain opinions from MultiCASE Inc., Optivia Biotechnology and Takara Bio Europe AB, seeing what participants say and do
  • Discussion of what stimulates and restrains companies and the market - examine forces affecting those technologies and their providers
  • Prospects for established firms and those seeking to enter the industry - discover what the future holds, helping you stay ahead in knowledge.

There you will find quantitative and qualitative analyses with independent predictions. That way you will receive information that only our report contains, staying informed on business intelligence.

Data and discussions found nowhere else, helping your research, analyses and decisions

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's new study is for everybody needing analyses of the pharma ADMET testing market and that industry's leading companies. There you will find data, trends and predictions. Stay ahead by getting that report here now.

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Market for ADMET Testing
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analysis
  • 1.5 Who Is This Study For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. An Introduction to ADMET Testing

  • 2.1 What Is ADMET Testing?
    • 2.1.1 Absorption
    • 2.1.2 Distribution
    • 2.1.3 Metabolism
    • 2.1.3.1 MIST Guidelines
    • 2.1.4 Excretion
    • 2.1.5 Toxicology
  • 2.2 The Role of ADMET Testing in Biosimilarity
  • 2.3 Trial Design and Execution
    • 2.3.1 Phases of Drug Development
      • 2.3.1.1 Phase 0 Trials: Establishing Pharmacodynamic and Pharmacokinetic Properties
      • 2.3.1.2 Phase I Trials: First-In-Human Studies
      • 2.3.1.3 Phase II Trials: Proof-Of-Concept
      • 2.3.1.4 Phase III Trials: Preparing for Approval Applications
      • 2.3.1.5 Post-Marketing Studies
    • 2.3.2 Reducing Attrition Rates in Drug Development through Predictive ADMET
    • 2.3.3 Benefits of Outsourcing

3. ADMET Testing: World Market 2015-2025

  • 3.1 Pharma R&D Expenditures by Phase, 2014
    • 3.1.1 The Impact of the Economy on the ADMET Testing Market, 2008-2014
    • 3.1.2 Big Pharma Companies Are the Leading Clients for CROs
  • 3.2 The ADMET Testing Market 2015-2025
    • 3.2.1 What Will Drive Growth in ADMET Testing 2015-2025?
    • 3.2.2 The ADMET Testing Market: Overall Revenue Forecast 2015-2025

4. ADMET Testing: Revenue by Segment 2015-2025

  • 4.1 Which Market Sector Will Account for the Most Revenue from 2015-2025?
  • 4.2 Rising Demand for Predictive ADMET Testing throughout the Decade
  • 4.3 In Vitro ADMET Testing Market
    • 4.3.1 In Vitro ADMET Testing: Drivers and Restraints
  • 4.4 In Vivo ADMET Testing Market
    • 4.4.1 In Vivo ADMET Testing: Drivers and Restraints
  • 4.5 In Silico ADMET Testing
    • 4.5.1 In Silico ADMET Testing: Drivers and Restraints

5. ADMET Testing: Leading Developed Markets 2015-2025

  • 5.1 Leading National Markets for ADMET Testing 2014
  • 5.2 ADMET Testing: Leading National Market Forecasts 2015-2025
  • 5.3 North America as a Destination for Drug Development
    • 5.3.1 The US: The Largest National Market for ADMET Testing 2015-2025
      • 5.3.1.1 Government Programs to Improve ADMET in the US
    • 5.3.2 The US: ADMET Testing Revenue Forecast 2015-2025
  • 5.4 The Outlook for ADMET Testing in the EU5 2015-2025
    • 5.4.1 Rewriting the Rules for Clinical Trials in the EU: Clinical Trials Regulation
    • 5.4.2 EU5: Overall Market and Leading National Market Forecasts 2015-2025
    • 5.4.3 Germany: Market Forecast 2015-2025
    • 5.4.4 The UK
      • 5.4.4.1 Overcoming Challenges in UK Clinical Trials
      • 5.4.4.2 UK ADMET Testing Market Forecast 2015-2025
    • 5.4.5 France: Market Forecast 2015-2025
    • 5.4.6 Italy: Market Forecast 2015-2025
    • 5.4.7 Spain: Market Forecast 2015-2025
  • 5.5 Japan Is Being Challenged by Neighbouring Emerging Markets
    • 5.5.1 Growth for ADMET Testing in Japan 2015-2025

6. ADMET: Leading Emerging Markets 2015-2025

  • 6.1 Leading Emerging Markets for ADMET Testing 2014
    • 6.1.1 Benefits of Conducting ADMET Testing in Emerging Markets
    • 6.1.2 Challenges of Conducting Non-Clinical Studies in Emerging Markets
  • 6.2 Strong Growth Forecast for Emerging ADMET Testing Markets 2015-2025
  • 6.3 ADMET in Asia Pacific: An Emerging Market Perspective
    • 6.3.1 China Will be the Largest Emerging Market for ADMET Testing in 2025
      • 6.3.1.1 CRO Investments and Partnerships in China
      • 6.3.1.2 Chinese ADMET Testing Market Forecast 2015-2025
    • 6.3.2 India as a Hub for Clinical Trials
      • 6.3.2.1 Indian ADMET Testing Market Forecast 2015-2025
    • 6.3.3 South Korea
      • 6.3.3.1 Promoting Local Drug Development in South Korea
      • 6.3.3.2 Growth in the South Korean ADMET Market 2015-2025
  • 6.4 Russia
    • 6.4.1 Changing Drug Development Demands 2010-2015
    • 6.4.2 Russian ADMET Market Forecast 2015-2025
  • 6.5 Brazil: The Largest Market for Drug Development in Latin America 2015-2025
    • 6.5.1 Brazilian ADMET Testing Market Forecast 2015-2025

7. Leading Companies in the ADMET Testing Industry 2014

  • 7.1 Agilent Technologies, Inc.
    • 7.1.1 Agilent Technologies, Inc.: Historical Revenues 2011-2014
    • 7.1.2 Agilent Technologies, Inc. Acquires Cartagenia
  • 7.2 Dassault Systèmes: Acquires Accelrys and forms BIOVIA
    • 7.2.1 Accelrys: Historical Revenues 2011-2013
  • 7.3 Cyprotex
    • 7.3.1 Cyprotex Acquires CeeTox
    • 7.3.2 Cyprotex Historical Revenues, 2010-2014
  • 7.4 Bio-Rad Laboratories, Inc.
    • 7.4.1 Bio-Rad Laboratories, Inc.: Historical Revenues 2011-2014
  • 7.5 Quintiles
    • 7.5.1 Expanding in Developed and Emerging Markets
  • 7.6 Increasing Asian Regional Reach
    • 7.6.1 CMIC Recent and Future Performance Analysis: An Asian Specialist
  • 7.7 Charles River Laboratories Is an Expert in Pre-Clinical Services
  • 7.8 WuXi PharmaTech
    • 7.8.1 WuXi Acquires XenoBiotic Laboratories
    • 7.8.2 WuXi Enters the Clinical Trial Services Market
  • 7.9 Promega Corporation
  • 7.10 Merck KGaA's Acquisition of Sigma Aldrich

8. ADMET Testing Market: Industry Trends 2015-2025

  • 8.1 Strengths and Weaknesses of the ADMET Testing Market
  • 8.2 Opportunities and Threats in the ADMET Testing Market
  • 8.3 ADMET Testing Market: STEP Analysis 2015-2025
    • 8.3.1 Social Factors Affecting ADMET 2015-2025
    • 8.3.2 Drug Developers Must Deal with Ethical Concerns for Animal Testing
  • 8.4 Improving Technology for More Efficient Testing: High-Throughput Evaluation and In Vivo-Like Models
  • 8.5 Economic Considerations for ADMET Testing 2015-2025
    • 8.5.1 Demand for Predictive ADMET Testing
  • 8.6 Political and Regulatory Developments Affecting ADMET Testing 2015-2025
    • 8.6.1 Cutting Red Tape and Other Regulatory Developments in Drug Discovery and Development
    • 8.6.2 Strategic Partnering for Long Term Revenue Growth
    • 8.6.2.1 Sharing Risk Between Pharma and CROs
    • 8.6.3 A Note on CRO Selection
    • 8.6.3.1 Small Pharmaceutical Companies and CROs
    • 8.6.4 CRO Consolidation is Decreasing the Number of Mid-Sized Market Players

9. Research Interviews

  • 9.1 Interview with Dr Roustem Saiakhov, President of MultiCASE, Inc.
    • 9.1.1 Addressing the Challenges in ADMET Testing
    • 9.1.2 Trends in the ADMET Testing Market
  • 9.2 Interview with Yong Huang, PhD, President and CEO of Optivia Biotechnology
    • 9.2.1 ADMET Services at Optivia Biotechnology
    • 9.2.2 Optivia's Partnership with Rhenovia Pharma: CNS Drug Development
    • 9.2.3 Optivia's Partnership with Hurel Corporation: In Vitro-to-In Vivo Correlation
    • 9.2.4 Challenges and Trends in Drug Discovery
    • 9.2.5 Growth of Optivia Biotechnology in the Future?
  • 9.3 Interview with Kristina Runeberg, Site Head of Takara Bio Europe AB
    • 9.3.1 Acquisition of Cellectis AB
    • 9.3.2 Addressing the Challenges in ADMET Testing
    • 9.3.3 Trends in the ADMET Testing Market

10. Conclusions from Our Study

  • 10.1 The World ADMET Testing Market in 2014
    • 10.1.1 A Market Dominated by the Developed Countries
  • 10.2 Strong Growth for the Overall Market 2015-2025
  • 10.3 Which CROs Can Take Best Advantage of Market Growth in the Next 10 Years?
    • 10.3.1 How Can CROs Specialise to Remain Competitive?

List of Tables

  • Table 1.1 ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 1.2 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2013 and 2014
  • Table 2.1 Pharmacokinetics: Description of ADME
  • Table 2.2 Drug Delivery Routes
  • Table 2.3 Biosimilar Guidance Drafted Using Elements of EU Guidelines, 2008-2015
  • Table 2.4 Founding Members of the ICH
  • Table 3.1 Breakdown of R&D Expenditures by Phase, 2014
  • Table 3.2 CRO Services Revenue by Customer Type, 2014
  • Table 3.3 ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 4.1 ADMET Testing Submarket Revenue ($bn) and Market Shares (%), 2014, 2019, and 2025
  • Table 4.2 ADMET Testing Submarket Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 4.3 In Vitro ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 4.4 In Vivo ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 4.5 In Silico ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.1 World ADMET Testing Market by National Market: Revenue ($bn) and Market Share (%), 2014
  • Table 5.2 ADMET Testing Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.3 ADMET Testing: Market Shares by Country, 2014, 2019 and 2025
  • Table 5.4 US ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.5 EU5 ADMET Testing Market by Country, 2014
  • Table 5.6 EU5 ADMET Testing Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.7 German ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.8 UK ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.9 French ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.10 Italian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.11 Spanish ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.12 Japanese ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 6.1 Leading Emerging Markets for ADMET Testing, 2014
  • Table 6.2 Population Statistics in BRIC Nations, May 2015
  • Table 6.3 English Proficiency in Emerging Markets, 2014
  • Table 6.4 ADMET Testing Market Forecast in Emerging Markets: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 6.5 Chinese ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 6.6 Indian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 6.7 South Korean ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 6.8 Russian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 6.9 Brazilian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 7.1 Selected Companies in the ADMET Testing Industry, 2015
  • Table 7.2 Selected Agilent Technologies MS Products, 2015
  • Table 7.3 Agilent Technologies: Revenue ($bn), AGR (%) and CAGR (%), 2011-2014
  • Table 7.4 Agilent Technologies: Revenue ($bn) and Revenue Share (%) by Sector, 2013 and 2014
  • Table 7.5 Accelrys: Revenue ($bn), AGR (%) and CAGR (%), 2011-2013
  • Table 7.6 Cyprotex ADME & PK Services, 2015
  • Table 7.7 Cyprotex In Vitro Toxicology Services, 2015
  • Table 7.8 Cyprotex In Silico Services, 2015
  • Table 7.9 Cyprotex: Revenue ($bn and £bn), AGR (%) and CAGR (%), 2011-2014
  • Table 7.10 Bio-Rad Laboratories: Revenue ($bn), AGR (%) and CAGR (%), 2011-2014
  • Table 7.11 Quintiles: Service Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
  • Table 7.12 CMIC: CRO Service Revenue ($bn and ¥bn), AGR (%) and CAGR (%), 2011-2014
  • Table 7.13 Charles River Laboratories: Revenue ($bn) and Revenue Share (%) by Sector, 2013 and 2014
  • Table 7.14 WuXi PharmaTech: Revenue ($bn) and CAGR (%) by Sector, 2012-2014
  • Table 8.1 ADMET Testing Market: Strengths and Weaknesses, 2015
  • Table 8.2 ADMET Testing Market: Opportunities and Threats, 2015
  • Table 8.3 ADMET Testing Market: STEP Analysis, 2015
  • Table 10.1 ADMET Testing Market by Sector: Revenue ($bn), CAGR (%) and Market Share (%), 2014, 2019 & 2025

List of Figures

  • Figure 2.1 Drug Design Process
  • Figure 2.2 ADMET Parameters
  • Figure 3.1 Breakdown of Pharma Clinical Spending by Phase, 2014
  • Figure 3.2 CRO Services Revenue by Customer Type, 2014
  • Figure 3.3 ADMET Testing Market: Drivers and Restraints, 2015-2025
  • Figure 3.4 ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 4.1 ADMET Testing Market Revenue ($bn) by Submarket, 2014, 2019 and 2025
  • Figure 4.2 ADMET Testing Submarket Shares (%), 2014
  • Figure 4.3 ADMET Testing Submarket Shares (%), 2019
  • Figure 4.4 ADMET Testing Submarket Shares (%), 2025
  • Figure 4.5 ADMET Testing Market Revenue ($bn) Forecast by Submarket, 2015-2025
  • Figure 4.6 In Vitro ADMET Revenue ($bn) Forecast, 2015-2025
  • Figure 4.7 In Vitro ADMET: Drivers and Restraints, 2015-2025
  • Figure 4.8 In Vivo Submarket Revenue ($bn) Forecast, 2015-2025
  • Figure 4.9 In Vivo ADMET: Drivers and Restraints, 2015-2025
  • Figure 4.10 In Silico Testing Submarket Revenue ($bn) Forecast, 2015-2025
  • Figure 4.11 In Silico Submarket: Drivers and Restraints, 2015-2025
  • Figure 5.1 World ADMET Testing Market by National Market: Market Share (%), 2014
  • Figure 5.2 World ADMET Testing Market by National Market: Market Share (%), 2019
  • Figure 5.3 World ADMET Testing Market by National Market: Market Share (%), 2025
  • Figure 5.4 US ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 5.5 EU5 ADMET Testing Market Share (%) by Country, 2014
  • Figure 5.6 EU5 ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 5.7 German ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 5.8 UK ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 5.9 French ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 5.10 Italian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 5.11 Spanish ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 5.12 Japanese ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 6.1 Leading Emerging Markets for ADMET Testing by Market Share (%), 2014
  • Figure 6.2 Cost Savings Available for Clinical Trials in Emerging Markets, 2014
  • Figure 6.3 Relative Competence in English in Emerging Markets, 2012
  • Figure 6.4 ADMET Testing: Emerging Market Revenue ($bn) Forecasts, 2015-2025
  • Figure 6.5 Chinese ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 6.6 Indian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 6.7 South Korean ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 6.8 Russian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 6.9 Brazilian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 7.1 Agilent Technologies: Revenue ($bn) and AGR (%), 2011-2014
  • Figure 7.2 Agilent Technologies: Revenue Share (%) by Sector, 2014
  • Figure 7.3 Accelrys: Revenue ($bn) and AGR (%), 2011-2013
  • Figure 7.4 Cyprotex: Revenue ($bn) and AGR (%), 2011-2014
  • Figure 7.5 Bio-Rad Laboratories: Revenue ($bn) and AGR (%), 2011-2014
  • Figure 7.6 Quintiles: Service Revenue ($bn) and AGR (%), 2010-2014
  • Figure 7.7 CMIC: CRO Service Revenue ($bn) and AGR (%), 2011-2014
  • Figure 7.8 Charles River Laboratories Clinical Trials: Revenue ($bn) by Sector, 2013 and 2014
  • Figure 7.9 WuXi PharmaTech: Revenue ($bn) by Sector, 2012-2014
  • Figure 10.1 ADMET Testing Market Revenue ($bn) by Sector, 2014, 2019 & 2025

Companies Listed

  • AbD Serotec (now part of Bio-Rad Laboratories)
  • ACEA Biosciences
  • Aegis Analytical Corp
  • Agenzia Italiana del Farmaco
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Agilent Technologies
  • Albany Molecular Research
  • Apredica, LLC
  • Associação Brasileira de CROs
  • Association of Clinical Trial Organisations (ACTO) [Russia]
  • AstraZeneca
  • Bayer
  • BD Biosciences
  • Beckman Coulter
  • Bio-Rad Laboratories
  • BIOVIA
  • Boehringer Ingelheim
  • Caliper Life Sciences
  • Cambridge Cell Networks
  • Catalent Pharma Solutions
  • Catalina Health (now part of InVentiv Health)
  • Celerion
  • Cellartis
  • Cellectis AB
  • Cellumen
  • Celsis International
  • Charles River Laboratories
  • ChemSW
  • Chinese Ministry of Commerce
  • Clinipace Worldwide
  • ClinStar (now part of PRA Health Sciences)
  • CMIC Holdings
  • Council for Economic Defense [Brazil]
  • Cromos Pharma
  • CROMSOURCE
  • Cyprotex
  • Department of Health and Human Services [US]
  • EF Education First
  • Entelos Holdings
  • Environmental Protection Agency [US]
  • EPS Holdings, Inc., formerly EPS Corporation
  • European Commission
  • European Medicines Agency (EMA)
  • Fish and Wildlife Service [US]
  • Food and Drug Administration (FDA) [US]
  • Frontage Laboratories
  • GCP ClinPlus
  • I3 Research (now part of InVentiv Health)
  • ICON plc
  • INC Research
  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
  • InVentiv Health
  • Harlan Laboratories (now part of Huntingdon Life Sciences)
  • Helmholtz Association
  • Helmholtz Zentrum München (German Research Center for Environmental Health)
  • Hisun Pharmaceuticals
  • Hospital Italiano of Buenos Aires
  • Huntingdon Life Sciences
  • JCL Bioassay Corporation (now part of CMIC)
  • Kendle (now part of INC Research)
  • Kforce Clinical Research (now part of InVentiv Health)
  • Korea Drug Development Fund
  • Korea Food and Drug Administration (KFDA)
  • Korea National Enterprise for Clinical Trials
  • L'Agence Nationale de Sécurité du Médicament (l'ANSM)
  • Les Entreprises du Medicament (LEEM)
  • Life Technologies Corporation
  • LSK
  • Malaysian Biotechnology Corporation
  • Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
  • Merck & Co.
  • Merck KGaA
  • Mitsubishi Gas Chemical Company, Inc.
  • MultiCASE
  • Nagoya University
  • National Association for Biomedical Research [US]
  • National Cancer Institute (NCI) [US]
  • National Center for Advancing Translational Sciences [US]
  • National Centre for Computational Toxicology [US}
  • National Enterprise for Clinical Trials [South Korea]
  • National Human Genome Research Institute [US]
  • National Institute of Environmental Health Sciences [US]
  • National Institutes of Health (NIH) [US]
  • National Toxicology Program [US]
  • New England Antivivisection Society
  • New York Stock Exchange
  • Noray Bioinformatics
  • Novartis
  • Novotech
  • Oncobiologics
  • Optivia Biotechnology
  • Organovo Holdings, Inc.
  • Parexel
  • PerkinElmer
  • Pharmaron
  • PharmaNet Development Group (now part of InVentiv Health)
  • PRA Health Sciences
  • Prodia Clinical Laboratory
  • Promega Corporation
  • Proteomics
  • ProTrials Research
  • Quintiles
  • ReSearch Pharmaceutical Services (now part of PRA Health Sciences)
  • Rosa & Co
  • Russian Ministry of Public Health
  • Samsung
  • Sekisui Medical Co.
  • Seoul National University Hospital Clinical Trials Center
  • Shanghai Clinical Research Center to
  • ShangPharma
  • Sigma-Aldrich
  • Simulations Plus
  • Sugi Medical Co. (now part of CMIC)
  • Taconic Biosciences
  • Takara Bio Europe AB
  • Takara Bio Inc
  • Tecan Group
  • Thermo Fisher Scientific
  • Tigermed Consulting
  • VelQuest
  • Vialis
  • Vietnam Ministry of Health Administration of Science, Technology and Training (ASST)
  • West Coast Clinical Trials
  • World Health Organization (WHO)
  • WuXi PharmaTech
  • Xceleron
  • XenoBiotic Laboratories
  • XenoTech (now part of Sekisui)
  • Yungjin Pharmaceutical
  • Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd
Back to Top